Itraconazole Powder + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ABPA

Conditions

ABPA

Trial Timeline

Feb 1, 2023 → Feb 27, 2024

NCT ID

NCT05667662

About Itraconazole Powder + Placebo

Itraconazole Powder + Placebo is a phase 2 stage product being developed by Pulmatrix for ABPA. The current trial status is terminated. This product is registered under clinical trial identifier NCT05667662. Target conditions include ABPA.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05667662	Phase 2	Terminated	Feb 1, 2023	Feb 27, 2024	ABPA